LPL Financial’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $498K | Sell |
10,697
-529
| -5% | -$25.4K | ﹤0.01% | 5024 |
|
|
2026
Q1 | $580K | Sell |
11,226
-6,265
| -36% | -$319K | ﹤0.01% | 4632 |
|
|
2025
Q4 | $869K | Buy |
17,491
+10,279
| +143% | +$500K | ﹤0.01% | 4211 |
|
|
2025
Q3 | $345K | Sell |
7,212
-9,270
| -56% | -$373K | ﹤0.01% | 4941 |
|
|
2025
Q2 | $520K | Buy |
16,482
+429
| +3% | +$13.7K | ﹤0.01% | 4355 |
|
|
2025
Q1 | $526K | Buy |
16,053
+3,312
| +26% | +$117K | ﹤0.01% | 4128 |
|
|
2024
Q4 | $461K | Buy |
12,741
+2,029
| +19% | +$71.4K | ﹤0.01% | 4170 |
|
|
2024
Q3 | $334K | Buy |
10,712
+552
| +5% | +$17.2K | ﹤0.01% | 4339 |
|
|
2024
Q2 | $272K | Buy |
10,160
+2,739
| +37% | +$79.4K | ﹤0.01% | 4354 |
|
|
2024
Q1 | $253K | Buy |
+7,421
| New | +$221K | ﹤0.01% | 4337 |
|
|
2023
Q3 | – | Sell |
-7,406
| Closed | -$223K | – | 4789 |
|
|
2023
Q2 | $223K | Sell |
7,406
-1,253
| -14% | -$43.8K | ﹤0.01% | 4078 |
|
|
2023
Q1 | $314K | Sell |
8,659
-795
| -8% | -$30.6K | ﹤0.01% | 3704 |
|
|
2022
Q4 | $337K | Sell |
9,454
-9,474
| -50% | -$329K | ﹤0.01% | 3565 |
|
|
2022
Q3 | $641K | Sell |
18,928
-4,591
| -20% | -$149K | ﹤0.01% | 2923 |
|
|
2022
Q2 | $680K | Buy |
23,519
+1,883
| +9% | +$53.9K | ﹤0.01% | 2919 |
|
|
2022
Q1 | $699K | Buy |
21,636
+64
| +0.3% | +$1.96K | ﹤0.01% | 2915 |
|
|
2021
Q4 | $629K | Buy |
21,572
+1,754
| +9% | +$53.2K | ﹤0.01% | 3077 |
|
|
2021
Q3 | $529K | Buy |
19,818
+1,370
| +7% | +$36.8K | ﹤0.01% | 3168 |
|
|
2021
Q2 | $568K | Sell |
18,448
-2,371
| -11% | -$72.7K | ﹤0.01% | 3054 |
|
|
2021
Q1 | $545K | Buy |
20,819
+3,874
| +23% | +$108K | ﹤0.01% | 2949 |
|
|
2020
Q4 | $426K | Buy |
16,945
+1,192
| +8% | +$25.7K | ﹤0.01% | 2904 |
|
|
2020
Q3 | $328K | Sell |
15,753
-127
| -0.8% | -$2.88K | ﹤0.01% | 2838 |
|
|
2020
Q2 | $377K | Buy |
15,880
+712
| +5% | +$15.7K | ﹤0.01% | 2653 |
|
|
2020
Q1 | $273K | Sell |
15,168
-403
| -3% | -$8.47K | ﹤0.01% | 2567 |
|
|
2019
Q4 | $369K | Sell |
15,571
-98
| -0.6% | -$2.38K | ﹤0.01% | 2617 |
|
|
2019
Q3 | $431K | Sell |
15,669
-128
| -0.8% | -$3.79K | ﹤0.01% | 2379 |
|
|
2019
Q2 | $523K | Sell |
15,797
-8,747
| -36% | -$300K | ﹤0.01% | 2246 |
|
|
2019
Q1 | $860K | Sell |
24,544
-2,850
| -10% | -$106K | ﹤0.01% | 1757 |
|
|
2018
Q4 | $910K | Buy |
27,394
+1,739
| +7% | +$74.8K | ﹤0.01% | 1603 |
|
|
2018
Q3 | $1.29M | Sell |
25,655
-18,800
| -42% | -$928K | ﹤0.01% | 1481 |
|
|
2018
Q2 | $2.66M | Buy |
44,455
+24,437
| +122% | +$1.27M | 0.01% | 972 |
|
|
2018
Q1 | $917K | Sell |
20,018
-1,109
| -5% | -$46.3K | ﹤0.01% | 1671 |
|
|
2017
Q4 | $842K | Sell |
21,127
-1,325
| -6% | -$52.4K | ﹤0.01% | 1655 |
|
|
2017
Q3 | $898K | Buy |
22,452
+2,298
| +11% | +$99.5K | ﹤0.01% | 1521 |
|
|
2017
Q2 | $869K | Buy |
20,154
+364
| +2% | +$13K | ﹤0.01% | 1464 |
|
|
2017
Q1 | $618K | Sell |
19,790
-4,423
| -18% | -$119K | ﹤0.01% | 1615 |
|
|
2016
Q4 | $628K | Sell |
24,213
-16,177
| -40% | -$361K | ﹤0.01% | 1539 |
|
|
2016
Q3 | $950K | Sell |
40,390
-1,585
| -4% | -$35.9K | 0.01% | 1236 |
|
|
2016
Q2 | $905K | Sell |
41,975
-16,536
| -28% | -$293K | 0.01% | 1239 |
|
|
2016
Q1 | $946K | Buy |
58,511
+20,025
| +52% | +$261K | ﹤0.01% | 1712 |
|
|
2015
Q4 | $517K | Buy |
38,486
+9,879
| +35% | +$153K | ﹤0.01% | 2164 |
|
|
2015
Q3 | $429K | Buy |
+28,607
| New | +$532K | ﹤0.01% | 1921 |
|
Other funds holding SUPN
SIMG
RHJA
GT
LPL Financial's SUPN Position: Q2 2026 in Review
LPL Financial reduced its Supernus Pharmaceuticals (SUPN) stake by 4.7% in Q2 2026, selling an estimated $25.4K and leaving 10,697 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #5024.
LPL Financial first reported a position in SUPN in Q3 2015 and has held it in 42 quarters since. The position peaked at $2.66M in Q2 2018. 137 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- LPL Financial held 10,697 shares of Supernus Pharmaceuticals worth $498K as of Q2 2026.
- LPL Financial sold 529 Supernus Pharmaceuticals shares in Q2 2026, an estimated $25.4K.
- Supernus Pharmaceuticals made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5024 holding.
- LPL Financial first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 42 quarters since.
- LPL Financial's Supernus Pharmaceuticals position peaked at $2.66M in Q2 2018.
- 137 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.